Loading...
4-1BBL–containing leukemic extracellular vesicles promote immunosuppressive effector regulatory T cells
Swatler, Julian Turos-Korgul, Laura Brewinska-Olchowik, Marta de Biasi, Sara Dudka, Wioleta Kominek, Agata Cyranowski, Salwador Pilanc, Paulina Mohammadi, Elyas
Swatler, Julian
Turos-Korgul, Laura
Brewinska-Olchowik, Marta
de Biasi, Sara
Dudka, Wioleta
Kominek, Agata
Cyranowski, Salwador
Pilanc, Paulina
Mohammadi, Elyas
Citations
Altmetric:
Genre
Journal article
Date
2022-03-17
Advisor
Committee member
Department
Cancer and Cellular Biology
Microbiology, Immunology and Inflammation
Microbiology, Immunology and Inflammation
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1182/bloodadvances.2021006195
Abstract
Chronic and acute myeloid leukemia evade immune system surveillance and induce immunosuppression by expanding proleukemic Foxp3+ regulatory T cells (Tregs). High levels of immunosuppressive Tregs predict inferior response to chemotherapy, leukemia relapse, and shorter survival. However, mechanisms that promote Tregs in myeloid leukemias remain largely unexplored. Here, we identify leukemic extracellular vesicles (EVs) as drivers of effector proleukemic Tregs. Using mouse model of leukemia-like disease, we found that Rab27a-dependent secretion of leukemic EVs promoted leukemia engraftment, which was associated with higher abundance of activated, immunosuppressive Tregs. Leukemic EVs attenuated mTOR-S6 and activated STAT5 signaling, as well as evoked significant transcriptomic changes in Tregs. We further identified specific effector signature of Tregs promoted by leukemic EVs. Leukemic EVs-driven Tregs were characterized by elevated expression of effector/tumor Treg markers CD39, CCR8, CD30, TNFR2, CCR4, TIGIT, and IL21R and included 2 distinct effector Treg (eTreg) subsets: CD30+CCR8hiTNFR2hi eTreg1 and CD39+TIGIThi eTreg2. Finally, we showed that costimulatory ligand 4-1BBL/CD137L, shuttled by leukemic EVs, promoted suppressive activity and effector phenotype of Tregs by regulating expression of receptors such as CD30 and TNFR2. Collectively, our work highlights the role of leukemic extracellular vesicles in stimulation of immunosuppressive Tregs and leukemia growth. We postulate that targeting of Rab27a-dependent secretion of leukemic EVs may be a viable therapeutic approach in myeloid neoplasms.
Description
Citation
Citation to related work
American Society of Hematology
Has part
Blood Advances, Vol. 6
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu